癌症切片检查市场－全球产业规模、份额、趋势、机会及预测（按产品类型、切片检查类型、应用、最终用户、地区和竞争格局划分），2021-2031年

全球癌症切片检查市场预计将从2025年的367.3亿美元成长到2031年的685.9亿美元，复合年增长率（CAGR）为10.97%。癌症切片检查是指采集体液或组织样本进行病理分析，以确认是否有恶性肿瘤及其类型。推动市场成长的因素包括全球肿瘤疾病发生率的上升以及人们对微创诊断方法（有助于早期发现）的日益青睐。例如，美国癌症协会估计，2024年美国将新增2,001,140例癌症病例。如此巨大的疾病负担直接导致诊断量增加，并推动了整个医疗保健系统对可靠切片检查产品的持续需求。

儘管该领域发展前景广阔，但仍面临许多限制其潜在扩张的重大障碍。其中一个主要障碍是合格病理学家和放射科医生短缺，而他们对于准确解读复杂检体至关重要。这种专业人才的短缺造成了诊断瓶颈，并限制了必要的切片检查服务的可及性，尤其是在资源匮乏的地区。

市场驱动因素

液态生物检体技术的突破性进展正在从根本上改变这一领域，为传统的组织取样提供了一种微创替代方案。这项创新只需简单的抽血即可检测循环肿瘤DNA (ctDNA)，从而实现对疾病进展和治疗反应的即时追踪，且无需承担手术风险。其提供全面基因组分析的能力正推动肿瘤科医师迅速采用此技术，尤其适用于组织取样困难或需要长期监测的患者。检测量的显着成长也印证了这项转变。 Guardant Health在2025年1月发布的「2024年第四季及全年初步业绩」报告中指出，临床癌症检测量约为206,700例，年成长20%，凸显了临床对这些先进诊断工具日益增长的需求。

同时，政府主导的癌症筛检计画扩展计画透过在大规模人群中系统化早期检测工作，显着提高了癌症诊断率。公共卫生部门正在加快推行针对常见恶性肿瘤（如乳癌、大肠癌和子宫颈癌）的强制性或建议性筛检项目，旨在透过早期疗育降低死亡率。例如，英国国家医疗服务体系（NHS）英格兰数位部门于2025年2月发布的《2023-2024年英格兰乳癌筛检计画》报告显示，该计画筛检了195万名女性，成功检测出16677例癌症，凸显了政府支持的诊断工作规模之大。鑑于日益加重的疾病负担，这种积极主动的方法至关重要。世界卫生组织（WHO）于2024年2月估计，2022年全球将新增2,000万例癌症病例，凸显了建立健全的全球筛检和切片检查基础设施的迫切需求。

市场挑战

熟练的病理学家和放射科医生短缺是限制全球切片检查市场扩张的一大瓶颈。这些专业人员在诊断流程中至关重要，负责指导精准的切片检查操作并解读复杂的组织检体。由于人手不足，医疗机构面临营运瓶颈，严重限制了其常规诊断能力。检体处理效率低下导致大量结果积压，检测结果週转时间延长。这实际上限制了可进行和计费的切片检查数量，导致切片检查耗材和设备的使用率低。反过来，这也阻碍了製造商的产生收入。

近期产业数据显示，人才短缺的严重性已被印证：根据英国皇家放射学院预测，英国2024年，英国临床放射学领域将出现30%的人才缺口。这一短缺迫使医院优先处理急诊病例，而非常规诊断筛检，从而有效降低了整体切片检查手术能力。由于缺乏执行和分析检测的专业人才，诊断产品的需求无法得到满足，人才短缺直接阻碍了市场成长。

市场趋势

人工智慧 (AI) 与组织病理学的融合正在革新切片检查样本的解读，显着提升了准确性和工作流程效率。基于海量组织影像资料集训练的演算法能够帮助病理学家高精度地识别恶性细胞，从而降低观察者间的差异，并消除诊断瓶颈。这项技术变革使检查室能够突破传统显微镜的限制，处理更多样本，并将临床数据整合到全面的病患画像中。 Tempus AI 于 2024 年 11 月发布的「2024 财年第三季财务业绩报告」预测，公司营收将达到 1.809 亿美元（年成长 33%），凸显了其人工智慧驱动的精准医疗平台日益增长的商业性应用。该平台利用海量的临床和分子数据来辅助诊断决策。

同时，用于组织采集的机器人辅助平台的引入，正在为手术精度和病人安全树立新的标准。这些自动化系统利用先进的导航技术和关节活动能力，能够到达传统手动技术难以触及的解剖位置，例如肺外周区域。透过稳定器械运动并提供即时视觉化，机器人平台显着提高了组织样本的诊断价值，同时最大限度地减少了对周围健康组织的损伤。这些系统的市场吸引力显而易见。在2025年1月发布的「2024年第四季及全年财务业绩」报告中，直觉外科公司（Intuitive Surgical）报告称，其Ion内视镜系统的手术量同比增长了73%，这反映出复杂切片检查手术正迅速转向机器人辅助介入。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球癌症切片检查市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按产品分类（设备、套件和耗材、服务）
  • 按切片检查类型（组织切片检查（针刺活检和手术切片检查）、液态生物检体、其他）
  • 依应用领域（乳癌、结肠癌、肺癌、前列腺癌、胰腺癌、卵巢癌等）
  • 依最终使用者划分（检测机构、医院/诊所检查室、学术机构、研究机构）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美癌症切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲癌症切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区癌症切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲癌症切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲癌症切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球癌症切片检查市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• QIAGEN NV
• Illumina, Inc.
• Guardant Health, Inc.
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• GRAIL, LLC
• Lucence Diagnostics Pte. Ltd.
• ANGLE plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cancer Biopsy Market is projected to expand from USD 36.73 Billion in 2025 to USD 68.59 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 10.97%. A cancer biopsy involves extracting fluid or tissue samples for pathological analysis to confirm the presence and specific type of malignancy. This market growth is supported by the rising global prevalence of oncological conditions and a growing preference for less invasive diagnostic methods that facilitate early detection. For instance, the American Cancer Society estimates that the United States will see 2,001,140 new cancer cases in 2024. This significant disease burden directly necessitates higher diagnostic volumes, fueling a sustained demand for reliable biopsy products across healthcare systems.

Despite these growth prospects, the sector faces considerable obstacles that limit its potential expansion. A primary impediment is the shortage of qualified pathologists and radiologists needed to accurately interpret complex samples. This scarcity of skilled professionals creates diagnostic bottlenecks and restricts the availability of essential biopsy services, particularly in regions with limited resources.

Market Driver

Technological breakthroughs in liquid biopsy modalities are fundamentally transforming the sector by providing a minimally invasive substitute for traditional tissue extraction. This innovation enables the detection of circulating tumor DNA (ctDNA) via a simple blood draw, allowing for real-time tracking of disease progression and treatment response without the risks inherent in surgical procedures. The ability to offer comprehensive genomic profiling is driving rapid adoption among oncologists, especially for patients with difficult tissue access or those requiring longitudinal monitoring. This shift is demonstrated by substantial volume growth; Guardant Health reported in its 'Preliminary Fourth Quarter and Full Year 2024 Results' in January 2025 that it conducted approximately 206,700 oncology clinical tests, a 20% increase from the prior year, highlighting the surging clinical demand for these advanced diagnostic tools.

Simultaneously, the broadening of government-led cancer screening initiatives is significantly boosting diagnostic volumes by systematizing early detection efforts across large populations. Public health authorities are increasingly implementing mandatory or recommended screening programs for high-prevalence malignancies such as breast, colorectal, and cervical cancers to lower mortality rates through timely intervention. For example, NHS England Digital's 'Breast Screening Programme, England, 2023-24' report from February 2025 notes that the program screened 1.95 million women and successfully detected 16,677 cancers, underscoring the massive scale of state-sponsored diagnostic activities. This proactive approach is essential given the growing disease burden; the World Health Organization estimated in February 2024 that there were 20 million new cancer cases globally in 2022, reinforcing the critical need for robust screening and biopsy infrastructure worldwide.

Market Challenge

The scarcity of skilled pathologists and radiologists acts as a severe bottleneck that directly hampers the expansion of the Global Cancer Biopsy Market. These specialists are essential to the diagnostic workflow, responsible for guiding precision biopsy procedures and interpreting complex tissue samples. When the workforce is insufficient to meet the rising volume of oncological cases, healthcare facilities face operational constraints that severely limit their daily diagnostic capacity. This inability to process samples efficiently results in significant backlogs and prolonged turnaround times for results. Consequently, the volume of performable and billable biopsy procedures is effectively capped, reducing the utilization rate of biopsy consumables and devices, which in turn stalls revenue generation for manufacturers.

The gravity of this workforce gap is confirmed by recent industry data. According to the Royal College of Radiologists, the clinical radiology sector in the United Kingdom faced a 30% workforce shortfall in 2024. Such a deficit compels hospitals to prioritize emergency cases over routine diagnostic screenings, leading to a tangible reduction in the overall throughput of biopsy procedures. This scarcity directly restricts market growth, as the demand for diagnostic products cannot be fully realized without the necessary professionals to execute and analyze the tests.

Market Trends

The integration of artificial intelligence into histopathology is revolutionizing the interpretation of biopsy samples by enhancing both accuracy and workflow efficiency. Algorithms trained on extensive datasets of tissue images assist pathologists in identifying malignant cells with high precision, thereby reducing inter-observer variability and addressing diagnostic bottlenecks. This technological shift allows laboratories to process higher sample volumes and integrate clinical data for more comprehensive patient profiling, moving beyond the limits of traditional microscopy. According to Tempus AI's 'Third Quarter 2024 Financial Results' from November 2024, the company reported revenue of $180.9 million, a 33% increase year-over-year, highlighting the growing commercial adoption of AI-enabled precision medicine platforms that leverage vast libraries of clinical and molecular data to support diagnostic decision-making.

In parallel, the adoption of robotic-assisted platforms for tissue acquisition is establishing new standards for procedural precision and patient safety. These automated systems utilize advanced navigation and articulation capabilities to access lesions in anatomical locations that are difficult to reach via conventional manual techniques, such as the peripheral lung. By stabilizing instrument movement and providing real-time visualization, robotic platforms significantly increase the diagnostic yield of tissue samples while minimizing trauma to surrounding healthy tissue. The market traction for these systems is evident; Intuitive Surgical reported in its 'Fourth Quarter and Full Year 2024 Financial Results' in January 2025 that the Ion endoluminal system saw a 73% growth in procedure volume during the fourth quarter compared to the prior year, reflecting a rapid shift towards robotic interventions for complex biopsy procedures.

Key Market Players

• QIAGEN N.V.
• Illumina, Inc.
• Guardant Health, Inc.
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• GRAIL, LLC
• Lucence Diagnostics Pte. Ltd.
• ANGLE plc

Report Scope

In this report, the Global Cancer Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biopsy Market, By Product

• Instruments
• Kits and Consumables
• Services

Cancer Biopsy Market, By Type of Biopsy

• Tissue Biopsies (Needle and Surgical Biopsies)
• Liquid Biopsies
• Others

Cancer Biopsy Market, By Application

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

Cancer Biopsy Market, By End User

• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic
• Research Centers

Cancer Biopsy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biopsy Market.

Available Customizations:

Global Cancer Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Biopsy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Kits and Consumables, Services)
  • 5.2.2. By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others)
  • 5.2.3. By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others)
  • 5.2.4. By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic, Research Centers)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Cancer Biopsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Type of Biopsy
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cancer Biopsy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Type of Biopsy
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Cancer Biopsy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Type of Biopsy
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Cancer Biopsy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Type of Biopsy
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Cancer Biopsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Type of Biopsy
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cancer Biopsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Type of Biopsy
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Cancer Biopsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Type of Biopsy
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Cancer Biopsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Type of Biopsy
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Cancer Biopsy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Type of Biopsy
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Cancer Biopsy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Type of Biopsy
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Cancer Biopsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Type of Biopsy
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cancer Biopsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Type of Biopsy
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Cancer Biopsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Type of Biopsy
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Cancer Biopsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Type of Biopsy
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Cancer Biopsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Type of Biopsy
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Cancer Biopsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Type of Biopsy
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Cancer Biopsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Type of Biopsy
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cancer Biopsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Type of Biopsy
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Cancer Biopsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Type of Biopsy
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Cancer Biopsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Type of Biopsy
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Cancer Biopsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Type of Biopsy
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cancer Biopsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Type of Biopsy
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Cancer Biopsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Type of Biopsy
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Cancer Biopsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Type of Biopsy
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cancer Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. QIAGEN N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina, Inc.
• 15.3. Guardant Health, Inc.
• 15.4. Thermo Fisher Scientific, Inc.
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Myriad Genetics, Inc.
• 15.7. Exact Sciences Corporation
• 15.8. GRAIL, LLC
• 15.9. Lucence Diagnostics Pte. Ltd.
• 15.10. ANGLE plc

16. Strategic Recommendations

17. About Us & Disclaimer